Indaptus Therapeutics, Inc. Material Event Summary

Indaptus Therapeutics, a biotech company developing cancer and infectious disease treatments, has undergone a major change in leadership and ownership. This shift marks a transition from the previous management team to a new group of controlling investors.

1. What happened?

A group of investors led by Yun Yao purchased 1,500,000 shares of Series A Convertible Preferred Stock from the company’s former largest shareholder, David Lazar. This deal triggered an immediate leadership shakeup: CEO Jeffrey Meckler resigned and was replaced by Junyi Dai. Additionally, directors Michael J. Newman and Robert J. Spiegel resigned, and the board has been completely reconstituted with the new investors' appointees.

2. When did it happen?

The parties signed the stock purchase agreement on March 18, 2026. The deal officially closed on March 23, 2026, making the leadership and board changes effective immediately.

3. Why did it happen?

The new investor group invested $11.2 million to gain a controlling stake. By acquiring Series A Preferred Stock—which carries significant voting rights—they secured control of the company quickly. The departure of the old leadership was a condition of the deal, allowing the new owners to install a team that aligns with their specific financial and strategic goals for the company’s cash and drug assets.

4. Why does this matter?

Indaptus is in the early stages of drug development and is not yet profitable. It relies on outside funding to support its Decoy20 and other programs.

• The "Controlled Company" Status: The new investors now hold shares representing 96.4% of the company’s voting power. This means the new owners have total authority over major decisions, such as mergers or raising additional capital, without needing approval from smaller shareholders.
• New Leadership Focus: New CEO Junyi Dai comes from an investment background. This suggests the company may prioritize managing its cash reserves and seeking business partnerships over expanding internal research.

5. Who is affected?

• Investors: Being a "controlled company" often leads to lower trading volume and higher price volatility. Minority shareholders now have effectively no say in how the company is run.
• The Company: Indaptus is shifting its strategy. The new CEO will now manage the company’s $12.3 million cash reserve.
• Patients: While the company’s drug trials remain the core business, the new leadership may change or pause certain trials to preserve capital.

6. What happens next?

The new team will file an SEC report detailing their long-term plans. They will need to clarify whether they intend to continue the current drug pipeline or seek a buyer for the company. Investors should watch future reports to see if the company cuts spending to extend its "cash runway."

7. What should investors know?

• Concentrated Control: With 96% of the vote, the new owners can act unilaterally. Smaller shareholders have lost their influence.
• Strategy Shifts: A finance-focused CEO often signals a "lean" approach. Expect a review of trial costs and a potential push for licensing deals.
• High Risk: This change creates "execution risk." The new team lacks a traditional pharmaceutical research background, which creates uncertainty regarding their ability to navigate the complex FDA regulatory process.

Bottom Line for Investors: This is a high-stakes transition. When a company becomes "controlled" by a single investor group, the stock often behaves differently than it did before. Your primary focus should be on the next SEC filing: look for signs of whether they plan to fund the existing drug pipeline or pivot toward a financial exit strategy.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and shouldn't be taken as professional investment advice. Always do your own research before making any trades!